Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences (NASDAQ: EXAS) has launched Cologuard Plus™, a groundbreaking colorectal cancer screening test demonstrating 95% sensitivity for cancer detection at 94% specificity - making it the most accurate noninvasive screening option to date.

The FDA-approved test shows significant improvements over its predecessor, including up to 40% reduction in unnecessary follow-up colonoscopies compared to the original Cologuard® test. Key features include 43% sensitivity for advanced precancerous lesions and 74% sensitivity for high-grade dysplasia. The test maintains a 99.98% negative predictive value.

Building on Cologuard's success of over 19 million screenings in the past decade, the new test is backed by the 20,000+ person BLUE-C study published in the New England Journal of Medicine. The test is covered by Medicare, included in USPSTF guidelines, and maintains strong patient adherence with 71% completion rate within 28 days.

Sera Prognostics (Nasdaq: SERA) announced significant changes to its Board of Directors. Jeff Elliott, currently a senior advisor at Boston Consulting Group and board member of Quanterix , will join the board on March 20, 2025. Elliott brings extensive experience in corporate strategy, business operations, and commercializing molecular diagnostics, having previously served as CFO and COO at Exact Sciences.

The company also announced that Ryan Trimble will retire and step down as director on June 30, 2025, after 14 years of service. Additionally, Marcus Wilson will not seek re-election at the 2025 Annual Meeting of Stockholders. Both departures are part of the board's ongoing efforts to refresh its composition and expertise.

These changes come at a important time as Sera begins leveraging its recent PRIME study results to build market presence for its PreTRM® test, focusing on improving maternal and neonatal health through pregnancy biomarker information.

Exact Sciences (NASDAQ: EXAS) has been awarded the 2025 Gallup Exceptional Workplace Award (GEWA) for the second consecutive year, recognizing its outstanding workplace culture and employee engagement. The company, known for cancer screening and diagnostic tests, maintains an exceptional employee engagement rate of 70%, significantly surpassing the global average of 23%.

According to Gallup's comprehensive workplace study, which analyzed over 3.3 million employees across 347 organizations, GEWA winners demonstrate 11 times higher ratio of engaged to actively disengaged employees compared to the global average. This recognition highlights Exact Sciences' success in creating an environment where employees feel valued and empowered, ultimately contributing to superior business outcomes in areas such as customer ratings, profitability, and productivity.

Exact Sciences (Nasdaq: EXAS), a leading cancer screening and diagnostic tests provider, has announced its management team's upcoming participation in two major investor conferences in March 2025.

The company will participate in a fireside chat at the TD Cowen Health Care Conference in Boston on Monday, March 3, 2025, at 10:30 a.m. ET. Additionally, they will deliver a presentation at the Raymond James Institutional Investors Conference in Orlando on Tuesday, March 4, 2025, at 1:05 p.m. ET.

Investors can access the webcasts of both events through the investor relations section of Exact Sciences' website at www.exactsciences.com.

Exact Sciences (EXAS) reported Q4 2024 revenue of $713 million, up 10% year-over-year, with Screening revenue of $553 million (+14%) and Precision Oncology revenue of $161 million (+0.4%). Full-year 2024 revenue reached $2.76 billion, a 10% increase.

The company recorded a Q4 net loss of $865 million ($4.67 per share), primarily due to $838 million in impairment charges related to the Thrive acquisition. Q4 adjusted EBITDA was $75 million, with an 11% margin. Cash position stood at $1.04 billion at quarter-end.

Exact Sciences plans to launch three new cancer tests in 2025: Cologuard Plus™ (Q2), which reduces false positives by 40%, Oncodetect™ (Q2) for molecular residual disease detection, and Cancerguard™ (H2), a multi-cancer screening test showing 62.3% overall sensitivity at 98.5% specificity.

Exact Sciences (Nasdaq: EXAS) has announced it will release its fourth quarter 2024 financial results after U.S. market close on February 19, 2025. The company will host a webcast and conference call at 5 p.m. ET on the same day to discuss the results and business progress.

Interested parties can access the live webcast at www.exactsciences.com. For the conference call, domestic callers should dial 888-330-2384, while international callers can use +1 240-789-2701. The access code for all callers is 4437608. A replay of the webcast will be available on the company's website.

Exact Sciences (NASDAQ: EXAS) revealed clinical validation data for its Oncodetect MRD test at ASCO GI 2025. The Alpha-CORRECT study demonstrated the test's effectiveness in detecting molecular residual disease in colorectal cancer patients, achieving 78% sensitivity post-surgery and 91% during surveillance, with specificities of 80% and 94% respectively.

The Beta-CORRECT study confirmed Oncodetect's prognostic value across stages II, III, and IV colon cancer and rectal cancer. The company plans to launch Oncodetect in Q2 2025 with Medicare coverage. Exact Sciences has established partnerships with NSABP and Flatiron Health to generate additional clinical evidence across multiple solid tumor types, including the CORRECT-I, CORRECT-II, and EXActDNA-003 studies.

Exact Sciences (NASDAQ: EXAS) will present 11 abstracts at the ASCO GI Symposium in January 2025, showcasing significant advances in cancer screening and diagnostics. The company's Oncodetect™ molecular residual disease (MRD) test demonstrated strong performance in Stage III colon cancer patients, with 78% sensitivity post-surgery and 91% during surveillance, along with specificities of 80% and 94% respectively.

The data reveals high adherence rates for the Cologuard® test across different demographic groups: African Americans (62%), Hispanic population (63%), Asian population (69%), and 45-49-year-olds (65%). These rates significantly exceed the generally accepted FIT adherence of 42%. New modeling data indicates that screening with triennial Cologuard results in fewer colorectal cancer cases, lower treatment costs, and higher life years gained compared to blood-based tests at perfect adherence.

Exact Sciences (NASDAQ: EXAS) has announced preliminary Q4 2024 results, expecting total revenue of $713 million, up 10% year-over-year. The company's Screening segment revenue reached $553 million (+14%), while Precision Oncology revenue was $161 million (+0.4%).

For full-year 2024, Exact Sciences anticipates total revenue of $2.76 billion, representing a 10% increase from 2023. The company's Screening revenue grew 13% to $2.104 billion, and Precision Oncology revenue increased 4% to $655 million.

Looking ahead to 2025, the company plans to launch three new cancer tests: Cologuard Plus for colorectal cancer screening, Oncodetect for molecular residual disease, and Cancerguard for multi-cancer screening.